Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Richard E. Cutler"'
Autor:
Ricardo Ribas, Sunil Pancholi, Aradhana Rani, Eugene Schuster, Stephanie K. Guest, Joanna Nikitorowicz-Buniak, Nikiana Simigdala, Allan Thornhill, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Mitch Dowsett, Stephen R. Johnston, Lesley-Ann Martin
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-15 (2018)
Abstract Background Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, cir
Externí odkaz:
https://doaj.org/article/d144720f2d924e96b49640bc5c504a90
Autor:
Carlos L. Arteaga, Jens Meiler, Christine M. Lovly, Darren Cross, Alshad S. Lalani, Richard E. Cutler, Vincent Miller, Jie He, David B. Solit, David M. Hyman, Michael F. Berger, Richard Lanman, Rebecca Nagy, Gregory R. Sliwoski, James P. Koch, Jonathan H. Sheehan, Monica Red Brewer, Ariella B. Hanker
Supplementary Figure S1. HER2L869R and HER3E928G cooperate to drive ERBB signaling output. Supplementary Figure S2. MG132 treatment restores expression of HER2T798I.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::154dda147285a5c156d4cbf8d35fdb31
https://doi.org/10.1158/2159-8290.22531999.v1
https://doi.org/10.1158/2159-8290.22531999.v1
Autor:
Carlos L. Arteaga, Jens Meiler, Christine M. Lovly, Darren Cross, Alshad S. Lalani, Richard E. Cutler, Vincent Miller, Jie He, David B. Solit, David M. Hyman, Michael F. Berger, Richard Lanman, Rebecca Nagy, Gregory R. Sliwoski, James P. Koch, Jonathan H. Sheehan, Monica Red Brewer, Ariella B. Hanker
Supplementary Table S1. Summary of mutations identified by FoundationOne profiling of the original, pre-neratinib skin metastasis. Supplementary Table S2. Frequency of HER2L869R and HER2T798I mutations. Supplementary Table S3. Sequencing of plasma DN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f218f8081ab31c8a70d37c3929898c2
https://doi.org/10.1158/2159-8290.22531996.v1
https://doi.org/10.1158/2159-8290.22531996.v1
Autor:
Carlos L. Arteaga, Nick V. Grishin, Richard B. Lanman, Vincent A. Miller, Alshad S. Lalani, Richard E. Cutler, Jie He, Massimo Cristofanilli, Eric H. Bernicker, Aju Mathew, Rebecca J. Nagy, Dhivya R. Sudhan, Paula I. Gonzalez-Ericsson, Lisa N. Kinch, Luigi Formisano, Sarah Croessmann
Table S1 - HER2 mutations Fig S1 - HER2 co-occur Fig S2 - Long Term Fulv. Fig S3 - L755S CI index Fig S4 - L755S RTprofile Fig S5 - Prot Align Fig S6 - Drug Assays Fig S7 - Quant of Drug Fig S8-11 - immunoblot Fig S12 - L755S mouse Fig S13 - S6 IHC -
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c53a2007a6aaecf8802c539e54e9801
https://doi.org/10.1158/1078-0432.22474497
https://doi.org/10.1158/1078-0432.22474497
Autor:
Carlos L. Arteaga, Alan Auerbach, Richard Bryce, Alshad S. Lalani, Richard E. Cutler, Francesca Avogadri-Connors, Justin M. Balko, Melinda Sanders, Paula I. González Ericsson, Sarah Croessmann, Mellissa J. Nixon, Luigi Formisano, Angel Guerrero-Zotano, Luis J. Schwarz, Dhivya R. Sudhan
Purpose:The phase III ExteNET trial showed improved invasive disease-free survival in patients with HER2+ breast cancer treated with neratinib versus placebo after trastuzumab-based adjuvant therapy. The benefit from neratinib appeared to be greater
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccdef9da4b82af81bb809312ab12ea87
https://doi.org/10.1158/1078-0432.c.6529268.v1
https://doi.org/10.1158/1078-0432.c.6529268.v1
Autor:
Carlos L. Arteaga, Nick V. Grishin, Richard B. Lanman, Vincent A. Miller, Alshad S. Lalani, Richard E. Cutler, Jie He, Massimo Cristofanilli, Eric H. Bernicker, Aju Mathew, Rebecca J. Nagy, Dhivya R. Sudhan, Paula I. Gonzalez-Ericsson, Lisa N. Kinch, Luigi Formisano, Sarah Croessmann
Purpose:We examined the role of ERBB2-activating mutations in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer.Experimental Design:ERBB2 mutation frequency was determined from large genomic databases. Isogenic knock-in E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::076dd429e25d3c11cb69e0237b39aeaa
https://doi.org/10.1158/1078-0432.c.6528801.v1
https://doi.org/10.1158/1078-0432.c.6528801.v1
Autor:
Carlos L. Arteaga, Alan Auerbach, Richard Bryce, Alshad S. Lalani, Richard E. Cutler, Francesca Avogadri-Connors, Justin M. Balko, Melinda Sanders, Paula I. González Ericsson, Sarah Croessmann, Mellissa J. Nixon, Luigi Formisano, Angel Guerrero-Zotano, Luis J. Schwarz, Dhivya R. Sudhan
Supplementary figure files
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7717b0f2dff6e0436730482ee3aeda
https://doi.org/10.1158/1078-0432.22476023
https://doi.org/10.1158/1078-0432.22476023
Autor:
Mellissa J. Nixon, Sarah Croessmann, Justin M. Balko, Carlos L. Arteaga, Paula Gonzalez Ericsson, Alshad S. Lalani, Melinda E. Sanders, Dhivya R. Sudhan, Francesca Avogadri-Connors, Angel Guerrero-Zotano, Alan Auerbach, Richard Bryce, Luigi Formisano, Luis J. Schwarz, Richard E. Cutler
Publikováno v:
Clinical Cancer Research. 25:771-783
Purpose:The phase III ExteNET trial showed improved invasive disease-free survival in patients with HER2+ breast cancer treated with neratinib versus placebo after trastuzumab-based adjuvant therapy. The benefit from neratinib appeared to be greater
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10ad751a195f1e7d9b46df2856ca2461
https://doi.org/10.1158/1078-0432.ccr-18-1131
https://doi.org/10.1158/1078-0432.ccr-18-1131
Autor:
Kyriakos P. Papadopoulos, Zhengping Wang, R. Donald Harvey, Yang Xu, Alain C. Mita, Ying Ou, Dawn E. Pinchasik, Apostolia Maria Tsimberidou, Lia Gore, Richard E. Cutler
Publikováno v:
British Journal of Clinical Pharmacology. 85:530-539
Aims Oprozomib is an oral, second-generation, irreversible proteasome inhibitor currently in clinical development for haematologic malignancies, including multiple myeloma and other malignancies. Oprozomib is a rare example of a small molecule drug t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a62cf9a8197aeb28e95ac15965f4262
https://doi.org/10.1111/bcp.13817
https://doi.org/10.1111/bcp.13817
Autor:
Teresa C. Dugger, Dhivya R. Sudhan, Helen Won, Carlos L. Arteaga, Mariela Huerta-Rosario, Kyungmin Lee, Alan J. Auerbach, Richard E. Cutler, Angel Guerrero-Zotano, James P. Koch, Alberto Servetto, Michael J. Wick, Richard Bryce, Dan Ye, Lisa N. Kinch, Paula Gonzalez Ericsson, Qi Liu, Yan Guo, Luigi Formisano, Alshad S. Lalani, Ariella B. Hanker, Monica Red Brewer
Publikováno v:
Cancer Cell
We developed neratinib-resistant HER2-mutant cancer cells by gradual dose escalation. RNA sequencing identified TORC1 signaling as an actionable mechanism of drug resistance. Primary and acquired neratinib resistance in HER2-mutant breast cancer pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d6fb05d584fcfb9202959d3cfe84e35
https://europepmc.org/articles/PMC7301608/
https://europepmc.org/articles/PMC7301608/